News

Front Lines on important SWOG results make up some of my most popular posts

The NCTN group chairs propose improvements in how we do correlative science

S1712 finds adding ruxolitinib increases response to TKIs in CML

Some trial results change the standard of care, while others affirm it. Both are valuable.

DART shows success in another rare cancer, and DART II is in the works

That's your PRO Core. Here's a five-year success update.

A new mentoring program is designed to engage APPs with SWOG and the NCTN